{"id":"NCT00689104","sponsor":"Astellas Pharma Inc","briefTitle":"Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","officialTitle":"A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04-28","primaryCompletion":"2009-03-24","completion":"2009-03-24","firstPosted":"2008-06-03","resultsPosted":"2012-10-17","lastUpdate":"2024-11-20"},"enrollment":2336,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Bladder, Overactive"],"interventions":[{"type":"DRUG","name":"Mirabegron","otherNames":["Myrbetriq","YM178"]},{"type":"DRUG","name":"Tolterodine","otherNames":[]},{"type":"DRUG","name":"Placebo to Mirabegron","otherNames":[]},{"type":"DRUG","name":"Placebo to Tolterodine","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Mirabegron 50 mg","type":"EXPERIMENTAL"},{"label":"Mirabegron 100 mg","type":"EXPERIMENTAL"},{"label":"Tolterodine SR 4 mg","type":"ACTIVE_COMPARATOR"}],"summary":"The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.","primaryOutcome":{"measure":"Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours","timeFrame":"Baseline and Week 12 (final visit)","effectByArm":[{"arm":"Placebo","deltaMin":-1.17,"sd":0.113},{"arm":"Mirabegron 50 mg","deltaMin":-1.57,"sd":0.113},{"arm":"Mirabegron 100 mg","deltaMin":-1.46,"sd":0.115},{"arm":"Tolterodine SR 4 mg","deltaMin":-1.27,"sd":0.112}],"pValues":[{"comp":"OG000 vs OG001","p":"0.003"},{"comp":"OG000 vs OG002","p":"0.010"},{"comp":"OG000 vs OG003","p":"0.11"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":218,"countries":["Australia","Austria","Belarus","Belgium","Bulgaria","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Iceland","Ireland","Italy","Latvia","Lithuania","Netherlands","Norway","Poland","Portugal","Romania","Russia","Slovakia","South Africa","Spain","Sweden","Switzerland","Ukraine","United Kingdom"]},"refs":{"pmids":["23182126","37160401","24246044"],"seeAlso":["https://www.astellasclinicalstudyresults.com/study.aspx?ID=35"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":494},"commonTop":["hypertension","Dry mouth"]}}